Comment from Paul Yang

Summary: Dr. Paul Yang, a clinician and professor at the Paul H. Casey Ophthalmic Genetics Division, supports the Haystack Project’s Petition for Rulemaking. He argues that the FDA should adopt a framework that considers disease-specific contexts—such as heterogeneity and progression rates in rare diseases—when evaluating whether clinical investigations are adequate and well-controlled.